German-Chinese coronavirus vaccine trial begins in China
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
MONDAY, MAY 16, 2022
MONDAY, MAY 16, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
German-Chinese coronavirus vaccine trial begins in China

Coronavirus chronicle

BSS/AFP
06 August, 2020, 09:00 am
Last modified: 06 August, 2020, 09:05 am

Related News

  • Over 700,000 refugees from Ukraine registered in Germany -Welt
  • WHO: Covid-19 falling everywhere, except Americas and Africa
  • N Korea reports first Covid-19 outbreak, orders lockdown
  • 34 volunteers chose to get covid. Here’s what scientists learned
  • Setback for Shanghai's Covid battle; Beijing focus on mass testing

German-Chinese coronavirus vaccine trial begins in China

The phase 1 trial in China involves 144 participants who will receive two doses 21 days apart

BSS/AFP
06 August, 2020, 09:00 am
Last modified: 06 August, 2020, 09:05 am
Photo:BSS/AFP
Photo:BSS/AFP

Clinical trials on humans have begun in China for a potential coronavirus vaccine developed by German pharmaceutical group BioNTech with Chinese company Fosun Pharma, the companies said Wednesday.

Seventy-two participants have already received their first dose following approval for the phase 1 trial from Chinese regulatory authorities, BioNTech and Fosun Pharma said in a statement.

The vaccine candidate, known as BNT162b1, is one of four based on BioNTech's proprietary mRNA technology.

Another, BNT162b2, is being evaluated in a global phase 3 trial conducted by BioNTech and US giant Pfizer which started on July 27.

The phase 1 trial in China involves 144 participants who will receive two doses 21 days apart.

Those aged 18-55 will be the first to take part, followed by older people.

Laboratories around the world are racing to find a vaccine to curb COVID-19, which has claimed more than 700,000 lives and upended the livelihoods of millions.

More than 200 candidate vaccines are currently being developed with roughly two dozen at the stage of clinical trials with human volunteers.

Several Chinese companies are at the forefront of the global vaccine race, while Russia has said it hopes to be the first in the world to produce a vaccine for the public, with a target date of September.

But the medicines will likely face heightened scrutiny given that the regulatory systems in both countries are far more opaque than they are in the West.

On top of the BioNTech/Pfizer candidate, two other Western coronavirus vaccines are in final phase three trials: one produced byUS biotech firm Moderna and the National Institutes for Health; and the other by the University of Oxford and Britain's AstraZeneca.

german / Chinese / Vaccine / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • PK Halder wants to return home
    PK Halder wants to return home
  • Exporters for continuation of 0.5% source tax for 5 years 
    Exporters for continuation of 0.5% source tax for 5 years 
  • Ranil Wickremesinghe. Photo: Reuters
    Sri Lanka out of petrol, economy in a precarious condition: PM Wickremesinghe

MOST VIEWED

  • Customers wait in front of a restaurant in Beijing, China April 15, 2022. REUTERS/Tingshu Wang/Files
    China's economy skids as lockdowns hit factories, retailers
  • A medical worker in a protective suit collects a swab from a resident at a makeshift nucleic acid testing site inside a residential compound under lockdown, amid the coronavirus disease (COVID-19) outbreak in Shanghai, China April 14, 2022. REUTERS/Xihao Jiang
    Shanghai aims for return to normal life from 1 June
  • South Korea's new President Yoon Suk-yeol signs a document as he works at the new Presidential office in Seoul, South Korea, May 10, 2022. Yonhap via REUTERS/File Photo
    S Korea says it will spare no effort to help North Korea amid Covid outbreak
  • North Korean leader Kim Jong Un wears a face mask amid the coronavirus disease (Covid-19) outbreak, while inspecting a pharmacy in Pyongyang, in this undated photo released by North Korea's Korean Central News Agency (KCNA) on May 15, 2022. KCNA via REUTERS
    Kim Jong Un orders North Korea military to 'stabilise' drug supply amid Covid outbreak
  • North Korea reports 15 more suspected Covid-19 deaths
    North Korea reports 15 more suspected Covid-19 deaths
  • Residents line up for nucleic acid tests during lockdown, amid the coronavirus disease (Covid-19) pandemic, in Shanghai, China, May 9, 2022. REUTERS/Aly Song
    Locked-down Shanghai to start gradually reopening malls, other businesses

Related News

  • Over 700,000 refugees from Ukraine registered in Germany -Welt
  • WHO: Covid-19 falling everywhere, except Americas and Africa
  • N Korea reports first Covid-19 outbreak, orders lockdown
  • 34 volunteers chose to get covid. Here’s what scientists learned
  • Setback for Shanghai's Covid battle; Beijing focus on mass testing

Features

Bitcoin, by far the largest cryptocurrency, is a terrible substitute for government-issued money. Photo: Reuters

Crypto’s wild week offers a much-needed warning

7h | Panorama
Karst Stone Paper Journal: Write on indestructible stone paper

Karst Stone Paper Journal: Write on indestructible stone paper

8h | Brands
Pesky bugs do not stand a chance against this automatic indoor insect trap

Pesky bugs do not stand a chance against this automatic indoor insect trap

8h | Brands
Wazeenah: Turning furniture into a canvas

Wazeenah: Turning furniture into a canvas

9h | Brands

More Videos from TBS

Where you can swim for Tk5

Where you can swim for Tk5

1h | Videos
Cultural activists pay tribute to Hassan Arif

Cultural activists pay tribute to Hassan Arif

4h | Videos
How PK Halder becomes a scamster

How PK Halder becomes a scamster

5h | Videos
How can you become proficient as a new team leader?

How can you become proficient as a new team leader?

5h | Videos

Most Read

1
The hostile welcome to Bangladesh
Bangladesh

The hostile welcome to Bangladesh

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
Union Capital asked to return Tk100cr FDR to BATBC 
Banking

Union Capital asked to return Tk100cr FDR to BATBC 

5
Bangladesh gas fields burnt $3m worth of gas in the air in 2021
Energy

Bangladesh gas fields burnt $3m worth of gas in the air in 2021

6
Impact of falling taka against US dollar
Banking

Taka losing more value as global currency market volatility persists

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab